Proove Biosciences Exclusively Licenses Established and Validated Genetic Testing Methods for Determining Pain Sensitivity and Response to Medication from UNC

Share Article

Three common haplotypes of the catechol-O-methyl-transferase (COMT) gene and multi-gene interactions published previously in Science[1]

We are thrilled by our collaboration with Dr. Diatchenko and Dr. Maixner.

Proove Biosciences, a commercial and research leader in Personalized Medicine, is excited to announce an exclusive licensing agreement with the University of North Carolina (UNC) at Chapel Hill’s School of Dentistry.

In April, 2014, Proove was chosen to present its award-winning pain and genetics study highlighting their research on key genes involved in pain sensitivity at the American Academy of Neurology. Proove has since attained exclusive rights to Professor Luda Diatchenko’s and William Maixner’s laboratories ground-breaking research regarding genetic regulation and the complex interplay of genetic variation within key genes (haplotypes) and between those genes (multi-gene interactions, COMT, ADBR3 & ABDR2 genes). Based on this research, predictions can be made for an individual’s sensitivity to pain as well as their response to commonly prescribed pain medicines.

UNC and Proove have been working together to commercialize these findings while simultaneously pursuing patent claims for the diagnostic use of genetic polymorphisms and related methods (US Application 20130244233).

“We are thrilled by our collaboration with Dr. Diatchenko and Dr. Maixner,” stated Proove Biosciences, founder and CEO, Brian Meshkin. “Their seminal research in the field of pain genetics at UNC has demonstrated the power of three key COMT gene haplotypes to predict an individual’s sensitivity to pain and to predict the efficacy of commonly prescribed medications for relieving their pain”.

Brian continued, “We are committed to incorporating important validated research findings like these into Proove’s suite of personalized medicine products. We have already incorporated many of these results, in concert with our own proprietary findings, into Proove’s Opioid Risk and Pain Perception tests.”

About Proove Biosciences
Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could’ve ever prescribed medications without knowing how a patient would respond. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll-free 855-PROOVE-BIO (855-776-6832).

[1] Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, Maixner W, Diatchenko L. Science. 2006 Dec 22; 314(5807):1930-3.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Keira Dazi
Proove Biosciences
+1 855-776-6832 Ext: 1594
Email >
@proovebio
Follow >
Proove Biosciences, Inc.
since: 01/2012
Like >